Tag Archives: economy

Do RESI San Diego and BIO Overlap?

12 May

By Sougato Das, President and COO, LSN

Sougato-Das

The fourth week of June is one of the largest gatherings of life science business development and investment professionals on the calendar, second only to JPM. If you are an early-stage company raising anywhere from $250K to $75M, that week in San Diego is not optional. The question most founders are asking right now is whether attending RESI means missing BIO.

The short answer is no. Here is why.
RESI partnering starts early morning on June 22. BIO Convention partnering does not start until early afternoon. That means you can run a full morning of investor meetings at RESI before BIO gets going. The two venues are about 15 minutes apart, making it straightforward to move between them in the afternoon. RESI has virtual days both that week and the following week, so any meetings that do not fit in person can be held on Zoom with no schedule conflicts.

If you find yourself double booked across both events on Monday afternoon, the partnering systems give you real options. Move the Convention meeting to another day. Move the RESI meeting to the morning or to a virtual slot. Or simply decide which meeting matters more for your specific raise. Having choices is better than not having them.

Fundraising is a numbers game. Companies with tight budgets need to maximize every hour and dollar spent in San Diego each week. RESI is not a scheduling conflict. It is more meetings with investors and pharma external innovation teams that are specifically focused on early-stage deals. Add it to your agenda.

Bonus: Increase your networking ROI by attending the many side events and receptions during Convention week. Luckily we’ve assembled the most complete list for you! Click here.

Register for RESI San Diego

Convention Week: How to Get the Most Investor/Inlicensor Meetings & Exposure 

5 May

By Sougato Das, President and COO, LSN

Sougato-Das

Prep for the June mega-events in San Diego, BIO Convention and the neighboring RESI, starts now. We’re 7 weeks out and it’s getting warm. In another week, the Heat is On by Glen Frey. Three weeks or so after that, scheduling starts and it’s Hot Hot Hot by Buster Poindexter. Finally, when partnering starts on June 22, it’s the Heat of the Moment by Asia. 80s music references aside, here are the top things you need to do NOW to ensure your company succeeds:

  1. Register. Want to meet investors funding seed through series B and pharma external innovation? There will be over 300 at RESI. Click here to take advantage of RESI early bird rates.
  2. Consider registering to pitch, with many opportunities throughout Convention week. Pitching at RESI puts you in front of a panel of well-aligned investors who are obligated to be interactive and give you feedback.
  3. Log into the partnering system and find your ideal partners. Repeat this every week to account for new registrants. At RESI this is straightforward as the LSN staff populates investors profiles very granularly based on the LSN Investor Database. Investors are carefully vetted. Searching for investors interested in a given modality, disease, geography, stage, etc. is fast. Searching for well-aligned partners in the larger Convention ecosystem can require more oversight (e.g. is an in-licensor looking for early stage, late stage or on-market assets?) Join my webinar to learn the best way to do this!
  4. Open as much availability on your calendar/agenda as possible. Convention week is NOT the time to block the early morning time slots because you want to sleep in 😉
  5. Send customized meeting requests. Meetings are more likely to be accepted if you spend some effort customizing each meeting request to the interests of the receiving company. Join my webinar to learn the best way to do this!
  6. Minimize the number of people from your company who are required to attend the meeting. The fewer people in the meeting the more likely it is to get scheduled (if it’s accepted).
  7. Follow-up on unanswered meeting requests. As someone who’s been behind the scenes running partnering at dozens of partnering events, I can tell you there is a complex series of variables that determines if your meeting request gets accepted. Sometimes it’s as simple as the person who would accept your meeting request did not register until later, even though his/her colleagues registered earlier. That’s why it’s important not let unanswered meeting requests languish indefinitely. Join my webinar to learn the best way to do this!
  8. Cancel ‘dead’ unanswered meeting requests. When you determine you won’t get a response for a given meeting request, cancel it to increase your meeting request allotment. Join my webinar to learn the best way to do this!
  9. When scheduling starts, immediately reach out to the other party for meetings that cannot be scheduled due to lack of mutual availability. You can also try reaching out to the partnering system administrators to see if they can help.
  10. Practice your meeting presentation to ensure everything gets finished in the allotted time. For Convention, 25 minutes is a good guide, as meetings can be far apart from each other. For RESI, 30 minutes as meetings are physically close together. To get between RESI and Convention, plan at least 20 minutes.
  11. Take advantage of virtual partnering. RESI provides virtual partnering during Convention week and the following week. Extend your ROI by continuing the momentum of Convention week into the next week.
  12. Be prompt about your follow-up the week after Convention.

Whew! I’m So Tired (by the Beatles) just writing this, I can’t imagine how I feel after I go through the Convention Week + RESI gauntlet! For more details on how to succeed at Convention & RESI, join my webinar on May 20 for all the best tips and tricks!

Sign Up the Webinar

Reception & Event List for Convention Week in San Diego

21 Apr

By Sougato Das, President and COO, LSN

Sougato-DasConvention week in San Diego has become much more than a single conference. One of the major events taking place during the week is RESI San Diego 2026, hosted by Life Science Nation on June 22, followed by four virtual partnering days on June 23–24 and June 29–30. This is the best place to secure meetings with early stage investors.

Around RESI and the Convention, investors, founders, pharmas, service providers, and regional delegations host receptions, networking events, investor forums, pitch sessions, private meetings, and educational programs across the city.

For attendees, the week often becomes a full schedule of opportunities that extends well beyond the official conference agenda. A company may attend RESI or Convention during the day and continue conversations at networking receptions and evening events across San Diego.

That is why having a compiled list of convention week events can be so valuable. Life Science Nation has curated a list of convention week events taking place throughout San Diego to help attendees better navigate the week. Covering Sunday, June 21 through Friday, June 26, the list serves as a useful resource for attendees looking to plan their schedules and make the most of their time in San Diego.

The list includes events for a range of audiences and interests, from investor networking and startup showcases to regional receptions, educational panels, business development gatherings, and informal social events. Some events are designed specifically for early-stage companies looking to connect with investors, while others are focused on strategic partnerships, market trends, or geographic regions.

Convention week can also be an important opportunity for companies to make the most of their time in San Diego. Rather than relying on one conference alone, attendees often use the week to build a broader schedule of meetings and introductions.

Whether attendees are focused on fundraising, partnering, business development, or networking, convention week offers a wide range of ways to connect.

View the Compiled List of Convention Week Events

Best Practices for Cap Table Management: What Founders Need to Know Before Their Next Raise 

31 Mar

By Sougato Das, President and COO, LSN

Sougato-Das

Early-stage companies often focus heavily on product development, market traction, and investor outreach—but one of the most critical foundations of long-term success lies in how equity is structured from the very beginning. A well-managed cap table is not just an administrative tool; it is a strategic asset that can influence fundraising outcomes, talent acquisition, and overall company growth.

To help founders navigate this essential aspect of building a company, J.P. Morgan and Polsinelli are hosting an upcoming webinar, “Best Practices for Cap Table Management.” This practical, founder-focused session is designed to equip early-stage leaders with the knowledge needed to make informed equity decisions and avoid costly mistakes down the road.

Register for the Webinar

The session will cover key fundamentals every startup team should understand, beginning with how to approach founder equity splits. Establishing fair and strategic ownership early on can prevent misalignment and friction as the company scales. From there, the discussion will move into dilution—an inevitable part of fundraising—and how founders can plan for and manage it effectively.

Another critical topic is the use of SAFE notes, which have become increasingly common in early-stage financing. While they offer flexibility, they can also introduce complexity if not fully understood. This webinar will break down how SAFE notes work and how they impact future equity distribution.

Importantly, the session will also explore how cap table structure directly affects fundraising outcomes. Investors often scrutinize ownership distribution, and a poorly structured cap table can create hesitation or even derail a deal. In addition, speakers will highlight the importance of building a thoughtful stock option pool, an essential tool for attracting and retaining top talent in competitive markets.

This webinar is particularly relevant for founders, CEOs, and CFOs who are looking to strengthen their financial strategy, prepare for upcoming funding rounds, and build companies that scale responsibly.

The session will take place on April 14, 2026 at 11:00 AM ET and will feature insights from industry experts Vanessa Blanco (J.P. Morgan), Alan Gould (J.P. Morgan), Sara Dauber (J.P. Morgan), Jeremy Arak (Polsinelli), and Sougato Das (Life Science Nation).

Attendees should note that this webinar will not be recorded and will be available exclusively to live participants, making attendance especially valuable for those looking to gain actionable insights in real time.

Sign Up Webinar

RESI Europe and European VC Coalition Seek to Boost EU Biotech Investment 

24 Feb

By Sougato Das, President and COO, LSN

Sougato-Das

RESI Europe is one of the major pieces in the puzzle of how to stimulate biotech and life science investing in Europe. In addition to the largest investor partnering conference coming to Lisbon on March 23, the European Life Sciences Coalition (ELSC), a new alliance of major venture capital firms advocating for increased funding and policy support for Europe’s biotech sector, has launched. The coalition includes leading investors such as Novo Holdings, Sofinnova Partners, Forbion, and Omega Funds, representing a combined €24 billion in life sciences assets and involvement in more than 1,400 companies. It launched in association with Invest Europe, whose 650+ members manage 60% of European private equity and venture capital, totaling €1.25 trillion in assets. Alongside major initiatives like the European Innovation Council, whose funded companies enjoy 50% reimbursement for attending RESI Europe, the ELSC hopes to bring new energy to the entrepreneurial sector of life sciences. 

Despite Europe’s strong pharmaceutical presence—five of the world’s top 10 pharma companies by revenue are European—and the industry supporting 29 million EU jobs, the region struggles to scale and retain biotech and life science innovation. The coalition highlights several challenges: 

  • Fragmented capital markets 
  • Declining numbers of specialized VC firms 
  • Regulatory hurdles 
  • Limited access to growth capital 

Europe accounts for only 7% of global venture capital, compared to 63% for the U.S. and 14% for China. Fortunately, events like RESI Europe create a forum where nearly all of the firms representing the 7% are available for partnering, acting as a facilitator to stimulate European life science investment. The dire need for this is underscored by the fact that nearly all EU-based biotechs that went public last year chose to list outside the EU, highlighting concerns about capital flight. 

ELSC members joined the coalition to help reverse these trends, emphasizing the need for sustained funding from both public and private sources across all stages of life sciences development. Industry leaders argue that Europe must increase investment in innovative medicines and treatments, and create supportive policy frameworks and forums, like RESI Europe, or risk losing access to cutting-edge therapies. The ELSC aims to work with policymakers and leverage Invest Europe’s network to strengthen Europe’s ability to fund and scale biotech innovation domestically.

Register for RESI Europe

Proseek Bio claims global bronze in San Francisco, strengthening Brisbane’s MedTech credentials 

27 Jan

Brisbane’s world renowned MedTech sector has again been recognised on the global stage, with local company Proseek Bio securing bronze at the Innovator’s Pitch Challenge during J.P. Morgan Healthcare Week in San Francisco. 

Proseek Bio, a participant in Brisbane Economic Development Agency’sMedTech Global Accelerator, competed against more than 90 international health technology companies and was recognised for its groundbreaking work in non-invasive blood tests aimed at earlier and more accurate detection of ovarian cancer, an area of significant unmet global health need. 

This year’s achievement continues Brisbane’s strong run of podium success at one of the world’s most influential healthcare investor forums, highlighting the city’s growing capability to develop, commercialise and scale life-changing medical technologies. 

Brisbane’s Innovator’s Pitch Challenge podium finishes include: 

  • 2023 Gold: Field Orthopaedics; Bronze: Max Kelsen 
  • 2024 Silver: Convergence Medical; Bronze: Gelomics 
  • 2025 Gold: Kimaritec 
  • 2026 Bronze: Proseek Bio 

BEDA’s MedTech Global Accelerator cohort attended the RESI JPM 2026 Investor Forum, in partnership with Life Science Nation, a leading US investor and life sciences networking platform. 

Lord Mayor Adrian Schrinner said the result was another strong sign of Brisbane’s rising reputation in health and medical innovation. 

“Brisbane’s MedTech talent continues to make waves on the world stage,” Cr Schinner said. 

“Proseek Bio’s bronze finish shows just how much innovation is coming out of our city and that Brisbane can go toe-to-toe with the best in the world – especially in lifesaving areas like women’s health and cancer detection. 

“We’re proud to support our innovators in building the global connections and partnerships they need to turn great ideas into reality.” 

Proseek Bio Founder and CEO, Professor Michelle Hill said the recognition marked a significant milestone for the company. 

“Winning bronze in this highly competitive challenge is a tremendous achievement for us,” Professor Hill said. 

“It validates the potential of our technology to make a real difference in women’s health and accelerates our ability to attract global partners and investment. 

“Support through BEDA’s MedTech Global Accelerator and its international network has been critical to our journey.” 

Now in its fourth year, the accelerator has helped more than 30 visionary companies secure $246 million in capital and create more than 250 jobs in Brisbane.  

BEDA’s FY26 MedTech Global Accelerator cohort included Aptium AI, BiVACOR, Cool Beans Underwear, Fibrosoft, Ketim Technologies, LORAI Health, Proseek Bio, QBiotics Group Limited, STARCO and Talius. 

For more information about the MedTech Initiative, visit https://choose.brisbane.qld.au/business/key-industries/health/medtech 

NAUGEN Global Innovation Showcase at RESI JPM 2026 

6 Jan

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

At RESI JPM 2026, NAUGEN will host the NAUGEN Global Innovation Showcase, a curated session spotlighting four innovative South Korea–based life science companies seeking global expansion through investment and strategic partnerships.

NAUGEN is a global innovation accelerator focused on advancing Novel, Advanced, and Unprecedented technologies across life sciences and deep tech. Through its incubation and acceleration platform, NAUGEN supports founders in scaling high-potential innovations by combining strategic and business development expertise with deep scientific and technological insight. NAUGEN is dedicated to identifying and cultivating breakthrough technologies that remain undiscovered by global markets and accelerating their path toward global competitiveness.

In partnership with George Mason University, NAUGEN recently launched the Northern Virginia International Soft Landing Accelerator (NISA). NISA is designed to help international startups establish and grow their presence in the United States by providing access to investor and partner networks, market-entry support, and lab and office space within Northern Virginia’s rapidly growing innovation ecosystem. Through NISA, global founders receive strategic mentoring, warm introductions to U.S. capital and corporate partners, and a clear pathway to scaling their businesses in the U.S. market.

As part of RESI JPM 2026, the NAUGEN Global Innovation Showcase will feature four companies representing a diverse range of therapeutic, regenerative, and medical-device innovations.

Session Details 

NAUGEN Global Innovation Showcase 
Date & Time: Monday, January 12, 2026 | 1:00–1:50 pm PST 
Location: Golden Gate B, Marriott Marquis San Francisco 

All investors and strategic partners interested in learning more about emerging life science innovations with global market potential are welcome to attend.

RSVP to NAUGEN Global Innovation Showcase

Participating Companies:

NexThera (https://nexthera.org
NexThera is a privately held, clinical-stage biotech company developing next-generation treatments for eye diseases and cancer. Its lead program, NT-101, is a first-in-class topical eye-drop therapy for wet age-related macular degeneration (AMD) and has shown encouraging safety and early clinical signals in a U.S. Phase 1/2 study. NT-101 uses a proprietary formulation that allows the medication to remain on the eye surface longer and reach the back of the eye effectively, offering a potential non-injection alternative for patients who currently rely on intravitreal treatments.


Karis Bio (https://karisbio.com
Karis Bio is a clinical-stage biotech company developing a first-in-class hiPSC-derived endothelial cell therapy to promote new blood vessel formation for ischemic cardiovascular diseases. The company has established a non-viral, non-integrating reprogramming and xeno-free differentiation platform that produces highly pure (>99%) endothelial cells with long-term safety. Its lead assets target severe peripheral artery disease (PAD) and coronary artery disease (CAD), where preclinical studies have demonstrated robust vascular regeneration and improved tissue perfusion.


MedicosBiotech (https://www.medicosbiotech.com
MedicosBiotech is a regenerative biomaterials company developing spider silk protein–based wound care solutions. The company has achieved the world’s first scalable production of full-length spider silk protein using E. coli, enabling high-purity and cost-efficient manufacturing. Its lead product, CureSilk, has demonstrated superior healing in chronic wound models, including diabetic foot ulcers and pressure ulcers, outperforming FDA-approved comparators in preclinical studies. MedicosBiotech is expanding its platform toward broader applications in regenerative medicine.


ShoeallS (https://shoealls.com/en
ShoeallS is a technology-driven company developing functional and smart medical footwear powered by its proprietary magnetic vibration module, which has been shown to enhance blood circulation and help alleviate pain. Building on its certified medical-device platform, ShoeallS is advancing next-generation smart shoes that integrate self-powering modules, embedded sensors, and AI-based monitoring to enable real-time patient-health insights. The company is expanding from functional footwear into a broader smart healthcare solution.